Tags : Bi-Specific Antibodies

GSK Expands its License Agreement with Zymework to Develop and

Shots: Zymework to receive preclinical, development & commercial milestone payments and royalties on WW sales. GSK to get an option to develop and commercialize bi-specific candidates for multiple indications including infectious diseases utilizing Zymeworks’ heavy-light chain pairing technology of Azymetric platform In 2016, the companies collaborated to develop & commercialize up to six bispecific antibodies […]Read More